These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17538637)

  • 1. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells.
    Fu X; Tao L; Zhang X
    Gene Ther; 2007 Aug; 14(16):1218-25. PubMed ID: 17538637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
    Fu X; Tao L; Cai R; Prigge J; Zhang X
    Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
    Li H; Dutuor A; Tao L; Fu X; Zhang X
    Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transmembrane domain of the large subunit of HSV-2 ribonucleotide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that result in ras activation.
    Smith CC; Luo JH; Hunter JC; Ordonez JV; Aurelian L
    Virology; 1994 May; 200(2):598-612. PubMed ID: 8178446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.
    Fu X; Tao L; Li M; Fisher WE; Zhang X
    Clin Cancer Res; 2006 May; 12(10):3152-7. PubMed ID: 16707615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.
    Peng T; Hunter JR; Nelson JW
    Virology; 1996 Feb; 216(1):184-96. PubMed ID: 8614985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway.
    Perkins D; Pereira EF; Gober M; Yarowsky PJ; Aurelian L
    J Virol; 2002 Feb; 76(3):1435-49. PubMed ID: 11773417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of herpes simplex virus type 2 protein ICP10 PK rescues neurons from apoptosis due to serum deprivation or genetic defects.
    Perkins D; Yu Y; Bambrick LL; Yarowsky PJ; Aurelian L
    Exp Neurol; 2002 Mar; 174(1):118-22. PubMed ID: 11869040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth-compromised HSV-2 vector Delta RR protects from N-methyl-D-aspartate-induced neuronal degeneration through redundant activation of the MEK/ERK and PI3-K/Akt survival pathways, either one of which overrides apoptotic cascades.
    Laing JM; Golembewski EK; Wales SQ; Liu J; Jafri MS; Yarowsky PJ; Aurelian L
    J Neurosci Res; 2008 Feb; 86(2):378-91. PubMed ID: 17893911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
    Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
    Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth.
    Smith CC; Nelson J; Aurelian L; Gober M; Goswami BB
    J Virol; 2000 Nov; 74(22):10417-29. PubMed ID: 11044086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is associated with the virion tegument and has PK activity.
    Smith CC; Aurelian L
    Virology; 1997 Aug; 234(2):235-42. PubMed ID: 9268154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
    Liu TC; Wakimoto H; Martuza RL; Rabkin SD
    Clin Cancer Res; 2007 Oct; 13(19):5897-902. PubMed ID: 17908985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
    Li H; Zeng Z; Fu X; Zhang X
    Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.